Navigation Links
Pharmacopeia Announces Management Team Changes
Date:2/28/2008

company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including seven clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic agreements with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. For more information please visit the company's website at http://www.pharmacopeia.com.

Contact:

Amy P. Sharpless

Corporate Communications Coordinator

Pharmacopeia, Inc.

(609) 452-3643

This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, goal, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward- looking statements include, but are not limited to, statements about the successful implementation of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop PS433540, a product candidate from its DARA program, Pharmacopeia's Phase 2 and Phase 1 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS178
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference
2. Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Reminder Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
4. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
5. West Pharmaceutical Services Announces Quarterly Dividend
6. Beijing 2008 Olympic Games Vegetable Supplier Considering Kiwa as a Supplier of Bio-Fertilizers & Kiwa Announces CEO Interview with WallSt.net
7. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
8. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
9. DARA BioSciences, Inc. Announces Appointment of New Director to Board
10. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
11. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... CA (PRWEB) May 26, 2015 ... the beginning of a long-term relationship with Veterinary ... behalf of its members to provide access to ... extremely pleased to count VGP as a dedicated ... arthritic dog patients nationwide. Concentrating and using stem ...
(Date:5/26/2015)... 26, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... regenerative medicine, today announced that all outstanding common share ... prior to their expiry on June 15, 2015, resulting ... "We thank our shareholders for their continued ... of Asterias. "This exercise of warrants represents a strong ...
(Date:5/26/2015)... NORTH CHICAGO, Ill. , May 26, 2015 ... biopharmaceutical company, announced today that it has completed ... and commercial presence in oncology. Pharmacyclics is a ... (ibrutinib), a first-in-class BTK-inhibitor used to treat hematological ... "The companies, shared expertise, combined with AbbVie,s broad ...
(Date:5/26/2015)... May 26, 2015 Just the characterization ... long-standing unmet biomedical need does not guarantee immediate acceptance. ... that has seen many prior failures is often met ... and use is an irony that is often an ... new start-up company, Asymmetrex has found that ...
Breaking Biology Technology:VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering 2VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering 3Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 3AbbVie Completes Acquisition of Pharmacyclics 2AbbVie Completes Acquisition of Pharmacyclics 3AbbVie Completes Acquisition of Pharmacyclics 4AbbVie Completes Acquisition of Pharmacyclics 5AbbVie Completes Acquisition of Pharmacyclics 6In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 2In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 3
... confer risk of, common diseases is empowering individuals to explore ... Webcast ... deCODE genetics,(Nasdaq: DCGN ) today announced the launch of deCODEme(TM), ... own,genome. Through your subscription to deCODEme(TM), you can learn what your ...
... Annual Analyst Day for Institutional Investors and Financial Analysts on ... November ... November 27 - - 19th Annual Piper Jaffray Health Care Conference on ... ) announced today that the Company will webcast its annual,meeting with institutional investors ...
... Nov. 15 Martek Biosciences,Corporation (Nasdaq: MATK ... European Patent Office (EPO) has ruled in favor ... docosahexaenoic acid (DHA) patents. The,modified claims of the ... broader than the claims that were previously upheld ...
Cached Biology Technology:deCODE Launches deCODEme(TM) 2deCODE Launches deCODEme(TM) 3deCODE Launches deCODEme(TM) 4Gen-Probe to Webcast Three Upcoming Presentations 2European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed 2European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed 3
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a leading ... services, and Morpho, a leading supplier of biometric ... produce the market,s most advanced biometrically-enabled time clock, ... NXG time clock is setting a bold, new ... data for the small and mid-size employer. When ...
(Date:4/2/2015)... Germany , April 2, 2015 ... fingerprint tests DERMALOG by far outperforms the strongest ... always maintaining high accuracy, the system is capable ... Hence, the speed proves up to be ten ... faster than its runner-up performance.      ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... who were treated with anti-tumor necrosis factor alpha, ... exacerbations than individuals taking a placebo. , This ... 2006 of the American Journal of Respiratory and ... Society. , Trevor T. Hansel, M.D., Ph.D., of ...
... the degenerative inflammatory bone disease, may be a sign of ... the Annals of the Rheumatic Diseases. , The authors base ... between 30 and 79. Most of them were female twins. ... to check for signs of osteoarthritis and a blood sample ...
... of Virology and Immunology (GIVI) have identified a previously unknown ... a finding that may lead to new approaches for controlling ... 2, 2006, in Proceedings of the National Academy of Sciences, ... of GIVI Director Warner C. Greene, MD, PhD, explains why ...
Cached Biology News:Monoclonal antibody reduces exacerbations in asthmatics 2Osteoarthritis may be sign of faster 'biological ageing' 2Gladstone investigators identify a new protective action for the powerful anti-HIV factor, APOBEC3G 2
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
C/EBPdelta Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Ubiquitin-like protein 4A (Ubiquitin-like protein GDX). [Source:Uniprot/SWISSPROT;Acc:P11441] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Mouse monoclonal [11C9] to Zeralenone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to BSA: Zeralenone...
Biology Products: